General

Stock price Loading… More on Euronext » General Stock Market Euronext Paris – Eurolist (compartiment C) Reuters / Bloomberg TRNG.PA / TNG.FP ISIN Code FR0005175080 Total number of shares outstanding 132,293,932 Initial Public Offering (IPO) March 26, 1998 Local Sector Index Next Biotech Financial Year Ends December 31

Financial reports

Years Quarter Interim Registration Document First Second Third Fourth 2024            XBRL(fr)   2023                XBRL(fr)    Amendment(fr)     2022            XBRL(fr) 2021              XBRL(fr) 2020             2019      … Continue reading Financial reports

Key figures

In € million except share and per share data 2023 2022 2021 2020 2019 Revenue 7.9 10.3 17.4 9.9 13.7 R&D Expense -29.6 -32.2 -32.9 -27.3 -31.4 G&A Expense -7.0 -7.9 -7.4 -6.5 -7.1 Net income (loss) -22.3 -32.8 -19.5 -17.2 -18.8 Net Cash Burn -24.0 -22.8 -10.0 -17.0 -20.5 Cash & Cash Equivalents 15.7… Continue reading Key figures

produits : 5 OVs teaser

AstraZeneca Transgene and AstraZeneca have entered into a collaboration agreement under which Transgene designs five innovative oncolytic viruses based on the Invir.IO™ platform. AstraZeneca can exercise an option on each of these candidates.

produits : TG6050

TG6050 Induce an immune response against tumors resistant to available treatments TG6050 is an oncolytic virus that has been engineered to express human IL-12 and an anti-CTLA4 antibody. TG6050 has been designed to be administered intravenously. By selectively targeting tumor cells and expressing IL-12 and an anti-CTLA4 antibody in the tumor microenvironment, TG6050 is expected… Continue reading produits : TG6050

produits : BT-001 teaser

BT-001 BT-001 is the first oncolytic virus from Invir.IO™ and is optimized to act as a Trojan horse. This novel immunotherapy approach has been designed to be highly targeted and is based on the patented viral backbone (VVcop TK-RR-). Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was… Continue reading produits : BT-001 teaser

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00

 

© 2025 Transgene - All rights reserved
Credits